New combo aims to boost lung cancer treatment in patients with bone metastases
NCT ID NCT06738160
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic therapy. Researchers will measure how many patients' tumors shrink and how long they live without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- narlumosbart (a RANKL inhibitor) and stereotactic body radiation therapy
- What this could lead to
- If successful, this combination could improve how well standard chemotherapy and immunotherapy work for people with advanced lung cancer that has spread to the bones.
- What could go wrong
- This is a small, early-phase trial with only 27 people, so results may not apply widely. The added treatments could also increase side effects like bone pain or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Preventive radiation may stop bone events before they start — a trial puts it to the test
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?